CA-SENSEFORTH.AI
12.8.2021 11:32:07 CEST | Business Wire | Press release
Conversational AI leader Senseforth.ai today announced a $14 million investment from Fractal (fractal.ai ), a global provider of artificial intelligence and analytics solutions to Fortune 500® companies. This investment will help Senseforth.ai scale and expand its footprint across Fractal’s clients globally. This investment also strengthens Fractal's conversational AI offerings as it advances on its mission to power every human decision in the enterprise.
Senseforth.ai’s patented and award winning zero-code platform A.ware automates customer experience across digital touchpoints for global enterprises. It is estimated that by 2022, 30% of customer experiences will be handled by conversational AI, up from 3% in 2017. A.ware makes it easy to build, train, deploy, and scale conversational AI solutions to drive revenue, reduce costs and increase operational efficiency.
Shridhar Marri, CEO and Co-Founder of Senseforth said, “This strategic investment creates a new growth blueprint for Senseforth.ai. We are thrilled to deliver on our vision 'to make technology humanlike', enabling continuous Human-AI interaction and transforming complex business processes.” He added, “We can now scale talent, accelerate growth, make more investments in R&D, and create incredible value for our clients.”
Announcing the strategic investment, Fractal’s Co-Founder, Group Chief Executive and Vice Chairman, Srikanth Velamakanni said, “Senseforth.ai’s founders Shridhar, Krishna and Ritesh have built a great team and a robust platform that’s deployed at scale with marquee clients like HDFC Bank. Senseforth’s technology is ahead of the competition, especially as evidenced by their performance benchmark on the leaderboard of Stanford Question Answering Dataset (SQuAD) 2.0.” Srikanth added, “We are excited to partner with the Senseforth.ai team to contribute to their next phase of growth.”
“We are inspired by Senseforth.ai’s work with the government of India to remove technology barriers in accessing citizen services for 700 million internet users through conversational AI. We are delighted to partner with Senseforth and expand conversational AI solutions to our clients,” said Pranay Agrawal, Fractal’s Co-founder and Chief Executive Officer.
Krishna Kadiri, Chief AI Officer and Co-Founder of Senseforth said, “Senseforth has a robust R&D and innovation culture and has already made its mark in the global ML benchmarks. This investment will help us enhance our deep learning capabilities and embed advanced cutting-edge research into A.ware.”
Don Vadakan, Chief Sales Officer at Fractal said, “Senseforth’s industry agnostic, multi-experience AI platform will drive next-generation digital solutions. We are excited to deliver powerful use cases across industries for both large and mid-size enterprises with A.ware from Senseforth.”
Ritesh Radhakrishnan, CTO, and Co-Founder of Senseforth said, “At Senseforth.ai, we have built A.ware, one of the most powerful and comprehensive Conversational AI Platforms in the market today. A.ware is already automating billions of conversations for enterprises across the world. This investment will help us further strengthen our technology foundation and scale our platform and products to become the undisputed market leader in the Conversational AI space.”
About Senseforth.ai
Senseforth.ai is a Conversational AI platform that enables automated human-like conversations at scale, between organizations and people. Founded with a vision to “make technology humanlike”, Senseforth.ai helps businesses acquire, engage and assist customers using AI-powered bots. As a preferred partner of choice for enterprises in North America, Europe and APAC, Senseforth.ai has implemented 100+ solutions that handle millions of conversations every month and has been recognized as a ‘Cool Vendor’ in Conversational AI Platforms in 2020 by Gartner, For more information, visit www.senseforth.ai
About Fractal
Fractal is one of the leading providers of AI and analytics globally to the world's most admired Fortune 500® companies. Fractal's mission is to power every human decision in the enterprise by bringing AI, engineering, and design to solve some of the world’s toughest problems.
Fractal's products include Qure.ai, to assist radiologists in making better diagnostic decisions; Crux Intelligence, to assist CEOs, and senior executives make better tactical and strategic decisions; Theremin.ai, to improve investment decisions; Eugenie.ai, to find anomalies in high-velocity data; and Samya.ai to drive next generation enterprise revenue growth management.
Fractal has more than 2,800 employees across 16 global locations, including the United States, UK, Ukraine, India, Singapore and Australia. Fractal has consistently been rated among India's best companies to work for, by The Great Place to Work® Institute; featured as a leader in the Customer Analytics Service Providers Wave™ 2021, Specialized Insights Service Providers Wave™ 2020 & Computer Vision Consultancies Wave™ 2020, by Forrester Research; and recognized as an "Honorable Vendor" in 2021 Magic Quadrant™ for data & analytics by Gartner. For more information visit fractal.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005361/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom